Fluoropharma Medical
FluoroPharma Medical, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of molecular imaging pharmaceuticals with initial applications in the area of cardiology in the United States. The company was founded in 2003 and is headquartered in Montclair, New Jersey.
Fluoropharma Medical (FPMI) - Total Assets
Latest total assets as of December 2016: $334.76K USD
Based on the latest financial reports, Fluoropharma Medical (FPMI) holds total assets worth $334.76K USD as of December 2016.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Fluoropharma Medical - Total Assets Trend (2007–2016)
This chart illustrates how Fluoropharma Medical’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Fluoropharma Medical - Asset Composition Analysis
Current Asset Composition (December 2016)
Fluoropharma Medical's total assets of $334.76K consist of 14.3% current assets and 85.7% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 7.4% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $7.42K | 2.2% |
| Intangible Assets | $279.55K | 83.5% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2007–2016)
This chart illustrates how Fluoropharma Medical's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Fluoropharma Medical's current assets represent 14.3% of total assets in 2016, a decrease from 82.7% in 2007.
- Cash Position: Cash and equivalents constituted 7.4% of total assets in 2016, down from 24.9% in 2007.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 83.0% of total assets, an increase from 0.0% in 2007.
- Asset Diversification: The largest asset category is intangible assets at 83.5% of total assets.
Fluoropharma Medical Competitors by Total Assets
Key competitors of Fluoropharma Medical based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $7.59 Billion |
|
ESSA Pharma Inc
NASDAQ:EPIX
|
USA | $110.50 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
Fluoropharma Medical - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Fluoropharma Medical generates 0.00x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Fluoropharma Medical is currently not profitable relative to its asset base.
Fluoropharma Medical - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.00 | 0.07 | 21.99 |
| Quick Ratio | 0.00 | 0.07 | 21.99 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-10.47 Million | $ -8.19 Million | $ 2.31 Million |
Fluoropharma Medical - Advanced Valuation Insights
This section examines the relationship between Fluoropharma Medical's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 17.76 |
| Latest Market Cap to Assets Ratio | 0.01 |
| Asset Growth Rate (YoY) | -65.7% |
| Total Assets | $334.76K |
| Market Capitalization | $3.07K USD |
Valuation Analysis
Below Book Valuation: The market values Fluoropharma Medical's assets below their book value (0.01 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Fluoropharma Medical's assets decreased by 65.7% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Fluoropharma Medical (2007–2016)
The table below shows the annual total assets of Fluoropharma Medical from 2007 to 2016.
| Year | Total Assets | Change |
|---|---|---|
| 2016-12-31 | $334.76K | -65.66% |
| 2015-12-31 | $974.86K | +18.86% |
| 2014-12-31 | $820.19K | -57.19% |
| 2013-12-31 | $1.92 Million | +18.73% |
| 2012-12-31 | $1.61 Million | -54.50% |
| 2011-12-31 | $3.55 Million | +274176.49% |
| 2010-12-31 | $1.29K | -47.14% |
| 2009-12-31 | $2.45K | -69.60% |
| 2008-12-31 | $8.05K | -69.44% |
| 2007-12-31 | $26.33K | -- |